FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average	Estimated average burden							
hours per response	: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Boyce Sarah				2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
	`	MACEUTICALS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/01/2018							below)	(give title hief Busi	Other (s below) ness Officer		pecify	
(Street)			92010		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S		(Zip)															
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			saction	ction 2A. Deemed Execution Date,		quired, Disposed of, or Benefi 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			d (A) or	5. Amou Securitie Beneficia Owned F	es For ally (D)		rm: Direct I or Indirect I	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common	Stock			01/0	1/201	.8	8 01/01/2018 J ⁽¹⁾ V 491 ⁽¹⁾ A \$42.755 5,760 D				D							
			Table II - I								osed of, convertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	s S Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to	\$49.25	01/02/2018	01/02/20	18	A		58,125		01/02/2019	(2)	01/01/2025	Common Stock	58,125	\$0	58,125	5	D	

Explanation of Responses:

- 1. Reporting 491 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 491 shares may not be sold until July 2, 2018.
- 2. Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

Remarks:

/s/B. Lynne Parshall, attorney-

01/02/2018

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.